Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2025 Earnings Conference Call
January 23, 2025 9:00 AM ET
Company Participants:
Richa Periwal – Head-Investor Relations and Analytics
Erez Israeli – Chief Executive Officer
M V Narasimham – Chief Financial Officer
Conference Call Participants:
Kunal Dhamesha – Macquarie
Neha Manpuria – Bank of America
Amey Chalke – JM Financial
Bino Pathiparampil – Elara Capital
Surya Narayan Patra – PhillipCapital
Damayanti Kerai – HSBC
Tushar Manudhane – Motilal Oswal Financial Services
Saion Mukherjee – Nomura
Foram Parekh – Bank of Baroda Capital Market
Anubhav Agrawal – UBS
Vishal Manchanda – Systematix
Shashank Krishnakumar – Emkay Global
Operator: Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy’s Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Dr. Reddy’s Laboratories Limited recently held its Q3 2025 earnings conference call where key figures and executives shared insights on the company’s performance and financial results. The call featured Head-Investor Relations and Analytics, Richa Periwal, Chief Executive Officer Erez Israeli, and Chief Financial Officer M V Narasimham, along with several conference call participants from prominent financial institutions.
The discussion likely included updates on the company’s financial performance, strategic initiatives, and outlook for the upcoming quarters. Dr. Reddy’s Laboratories Limited is a leading pharmaceutical company known for its innovative research and development efforts in the healthcare industry.
Overall, the conference call provided valuable information for investors, analysts, and stakeholders interested in the company’s growth trajectory and market position.
Impact on Individuals:
For individual investors, the insights shared during the earnings conference call can help inform investment decisions regarding Dr. Reddy’s Laboratories Limited. Understanding the company’s financial health, strategic direction, and upcoming opportunities can guide individual investors in making informed choices about their investment portfolios.
Impact on the World:
Dr. Reddy’s Laboratories Limited plays a significant role in the global healthcare industry, with its research and development efforts contributing to advancements in pharmaceuticals and healthcare solutions. The company’s performance and future outlook can impact the broader healthcare sector and have ripple effects on patients, healthcare providers, and other pharmaceutical companies around the world.
Conclusion:
In conclusion, the Q3 2025 earnings conference call of Dr. Reddy’s Laboratories Limited provided valuable insights into the company’s performance and outlook. As stakeholders digest the information shared during the call, they can better assess the company’s position in the market and make informed decisions moving forward.
